Tocilizumab for Covid-19 - The Ongoing Search for Effective Therapies
| Errataetall: |
CommentOn: N Engl J Med. 2020 Dec 10;383(24):2333-2344. - PMID 33085857 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:383 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 383(2020), 24 vom: 10. Dez., Seite 2387-2388 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Edmund [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 14.12.2020 Date Revised 07.12.2022 published: Print CommentOn: N Engl J Med. 2020 Dec 10;383(24):2333-2344. - PMID 33085857 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMe2032071 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318620391 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318620391 | ||
| 003 | DE-627 | ||
| 005 | 20231225165731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMe2032071 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318620391 | ||
| 035 | |a (NLM)33296566 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Edmund |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab for Covid-19 - The Ongoing Search for Effective Therapies |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.12.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: N Engl J Med. 2020 Dec 10;383(24):2333-2344. - PMID 33085857 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Jordan, Stanley C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 383(2020), 24 vom: 10. Dez., Seite 2387-2388 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:383 |g year:2020 |g number:24 |g day:10 |g month:12 |g pages:2387-2388 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMe2032071 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 383 |j 2020 |e 24 |b 10 |c 12 |h 2387-2388 | ||